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For the last 2000 years surgery has been the primary treat-
ment for patients with breast cancer. During this period,
surgical procedures for breast cancer became more exten-
sive and culminated in the radical mastectomy as
described by Halstead. Such extensive surgery was fuelled,
and perpetuated, by the widespread acceptance of the Hal-
steadian concept of tumour biology and tumour spread.
As a result of this, radical mastectomy dominated surgical
practice for breast cancer for almost 100 years [1]. How-
ever, with advances in our understanding of tumour biol-
ogy, these Halsteadian concepts were challenged. As a
result, novel, and less extensive, approaches to the surgical
treatment of breast cancer were initiated and evaluated in
a scientific manner.
Of particular importance were randomised controlled tri-
als of breast conserving surgery, which were compared
with mastectomy in a very careful manner. These trials
demonstrated that the more limited surgical procedures
resulted in as good a local control of disease, and the same
overall survival, when compared with more extensive sur-
gical procedures. Also, the importance of micrometastatic
disease and the impact of adjuvant therapies, which are
given after surgical resection of the primary tumour, and
their impact on survival have become clearer and well rec-
ognised [2].
In tracing the development of primary chemotherapy in
the management of patients with breast cancer, there are
an important group of patients who were first identified
over 50 years ago and in whom surgery, either radical or
conservation surgery is not appropriate. These are patients
with locally advanced breast cancer (defined as tumour
greater than 5 cm (T3), fixation of the tumour to skin and/
or chest wall (T4), skin oedema (peau d'orange), skin
ulceration, satellite nodules and/or infiltration, large
(>2.5 cm) or fixed/matted axillary lymph nodes (N2),
supraclavicular lymphadenopathy, and/or arm oedema).
If they are treated by mastectomy, more than 50% with
experience local disease recurrence and very few will sur-
vival 5 years or longer [3].
An alternative approach to the treatment of these patients
was necessary and one such approach was the use of pri-
mary (neoadjuvant) chemotherapy and/or radiotherapy
given prior to surgery. This approach was supported by the
evidence from studies in animal experimental tumour
models, which had indicated that primary chemotherapy
might be beneficial in terms of modulating of tumour
growth and improving survival if given prior to surgery
[4,5]. Therefore, with these pre-clinical studies in mind,
De Lana and colleagues reported the effect of treatment
with primary chemotherapy in patients with breast cancer
who had stage III disease. Vincristine and doxorubicin
were given to these patients as primary chemotherapy
with the intention of down-staging the disease in the
breast prior to subsequent loco-regional treatment [6].
The results were encouraging and substantial numbers of
patients responded well, with the primary tumour in the
breast being significantly reduced in size. Following on
from this and other clinical studies of patients with locally
advanced breast cancer, primary chemotherapy was given
to patients with breast cancers that were smaller and had
been previously considered to be suitable for surgery as
the initial treatment.
In many studies, clinical response rates of 75%, (complete
and partial) were obtained, with up to 30% of patients
Published: 10 August 2003
World Journal of Surgical Oncology 2003, 1:14
Received: 18 July 2003
Accepted: 10 August 2003
This article is available from: http://www.wjso.com/content/1/1/14
© 2003 Heys and Chaturvedi; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted 
in all media for any purpose, provided this notice is preserved along with the article's original URL.World Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/14
Page 2 of 4
(page number not for citation purposes)
having a complete clinical response and in whom there
was no residual tumour detectable in the breast by clinical
examination. Subsequently, many investigators have
reported similar findings when using primary chemother-
apy. Clinical response rates have usually ranged from 51%
to 93% [7,8]. Complete clinical responses occur in
approximately 20% of patients although in some series,
often using complex and prolonged chemotherapeutic
regimens, response rates (complete and partial) have been
as high as 90% [9]. More recent studies have demon-
strated that even higher clinical response rates can be
obtained by using newer chemotherapeutic agents. For
example, a combination of a taxane (docetaxel) and dox-
orubin can result in a clinical response rate of up to 95%
and as many as two thirds of patients have a complete
clinical response [10–12].
In patients who have had a complete clinical response to
chemotherapy, is surgery still necessary? The answer to
this question is certainly yes at the present time. It is
important to remember that whilst clinical responses are
excellent, with substantial numbers of patients having no
detectable tumour either clinically and/or as identified by
imaging (mammography, ultrasonography, magnetic res-
onance mammography), the pathological responses are
substantially less than the clinical ones.
When pathological response rates have been reported,
complete histological responses, where there is no resid-
ual tumour in the breast, have been reported to occur
from 3% to less than 20% of all patients [8,13]. Even with
the use of new and more potent chemotherapeutic agents
such as the taxanes, complete pathological responses can
be increased to 34%. This still means that at least two
thirds of patients will have residual tumour in the breast
following completion of primary chemotherapy [10–12].
It seems inappropriate, therefore, not to proceed to sur-
gery, with the intention of removing any residual tumour,
which is likely to be present in the breast.
Perhaps the necessity for this is not surprising if we con-
sider parallels in the management of testicular tumours.
Here, in this situation responses to chemotherapy, even in
patients with widespread metastatic disease, can be dra-
matic with elimination of distant disease and excellent
long term survival. However, even when treating patients
with widespread metastatic disease primarily with chem-
otherapy (before any surgery to the site of the primary
tumour in the testis), orchidectomy is usually performed
after completion of chemotherapy. This is because in up
to 12% of these patients there may be residual invasive
malignant cells, and also, patients may have in-situ malig-
nancy in the testis, with the consequent risk of disease
relapse or further development of another primary
tumour [14].
An important development in treating patients with pri-
mary chemotherapy (for any type of malignancy) would
be to be able to identify those patients with residual
tumour following completion of chemotherapy. At the
present time this is not possible, but imaging techniques
such as magnetic resonance mammography and positron
emission tomography may offer this possibility and thus
surgery may be avoided in selected patients. The presence
of residual tumour within the breast has a prognostic sig-
nificance for the patient in terms of overall survival. In the
NSABP-B18 trial of primary chemotherapy, patients in
whom the tumour had undergone a complete pathologi-
cal response had a significantly better survival than those
who had residual tumour remaining in the breast [15].
On the basis of the majority of patients having residual
tumour there is still a need for surgery in order to mini-
mise the risk of future local recurrence of disease in
patients who have received primary chemotherapy for
breast cancer. However, having made this decision as to
the requirement for surgery, how extensive should it be?
The accepted criteria for undertaking breast conservation
surgery in patients not receiving primary chemotherapy
are well know and understood. But just how appropriate
and applicable are they to patients who have undergone
primary chemotherapy?
Recently, McIntosh et al [16] reported a series of 173
women with large and locally advanced breast cancers
who had been treated with primary chemotherapy. Stand-
ard criteria that are normally used in patients with pri-
mary operable breast cancer were applied to patients
undergoing breast conservation surgery following com-
pletion of primary chemotherapy. The patients in this
series had in a local recurrence rate of only 2% if they
underwent breast conservation and, 7% if they had under-
gone mastectomy (median follow up was 62 months). In
patients who experienced local recurrence of disease there
was a significant reduction in overall survival when com-
pared with those who did not (27 months versus 62
months) [16].
Whether the local recurrence of disease was a predictor of
a poor prognosis or was the cause of metastatic disease
remains unclear. An important study, which allows fur-
ther insight, is the NSABP-B18 trial [15]. In this study,
1523 women were randomised to receive either primary
chemotherapy or surgery with adjuvant chemotherapy. In
patients whose tumours were considered initially to be
too large to be suitable for conservation surgery, but in
whom conservation surgery was actually undertaken fol-
lowing completion of primary chemotherapy, there was
an increased risk of local disease recurrence. The risk of
local recurrence was 16% when compared with just 10%
in those patients who proceeded to breast conservationWorld Journal of Surgical Oncology 2003, 1 http://www.wjso.com/content/1/1/14
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surgery as had been originally planned. In an updated
analysis of NSABP-B18, this difference was explained in
part by differences in patients' age and their initial clinical
tumour size prior to commencing chemotherapy, but
there is still a concern as to the adequacy and role of breast
conservation surgery in these patients [17].
This is an important issue that requires further considera-
tion. When a tumour responds to chemotherapy, with a
consequent reduction in its tumour size and a replace-
ment of the tumour cells by scar tissue, does the tumour
reduce size in a uniform symmetrical way? Alternatively,
does it reduce in size in an irregular, asymmetrical way
with the potential for residual tumour cells to be left in the
breast tissue away from the main tumour mass? If it is the
latter, which occurs, there are important implications for
the significance and appropriateness of what "clear mar-
gins" really means when treating patients who have
undergone primary chemotherapy with breast conserving
surgery.
In the potential for, and application of the use of primary
chemotherapy in the management of the common solid
cancers, its use in the treatment of patients and the lessons
learned are being applied to the management of patients
with other solid cancers. For example, the use of primary
chemotherapy, prior to undertaking surgery, is well
described in patients with advanced gastric and oesopha-
geal cancers [18,19], soft tissue sarcomas [20], ovarian
cancers [21] and non-small cell lung cancers [22].
It is clear from these, and other studies, that the use of pri-
mary chemotherapy will result in a down-staging of the
primary tumour with a subsequent increase in surgical
tumour resection rates. Significant numbers of patients
can then proceed to surgical resection of the tumour in
which this would not have been possible prior to the
administration of primary chemotherapy. Furthermore,
in terms of overall survival, there does appear to be evi-
dence accumulating that this is increased when compared
to patients not receiving primary chemotherapy but pro-
ceeding directly to surgery if this was technically feasible
[19–21,23].
However, it is interesting to note that whilst clinical
responses in terms of decreasing tumour size are good, the
same problems that are present in the management of
patients with breast cancer also apply to patients with
other cancer types. The pathological responses to primary
chemotherapy are significantly less than the clinical
responses. Moreover, the majority of patients treated with
primary chemotherapy will have residual tumour as
assessed histologically [18–22]. As for those patients
treated for breast cancer, in these patients with different
tumour types, subsequent surgical resection of probable
residual tumour is still necessary. Once there is a tech-
nique for accurately identifying those patients who do not
have any tumour remaining following completion of pri-
mary chemotherapy then again there is the possibility of
selected patients not requiring what are often major surgi-
cal procedures with significant morbidity and mortality.
As we are embarking into the third millennium, surgery is
still a key modality in the multidisciplinary management
of patients with breast cancer who receive primary chem-
otherapy. Nevertheless, the potential for avoidance of sur-
gery, at least in selected patients in whom there is no
residual tumour remaining is real and tangible, – if they
can be identified accurately. In other areas of breast cancer
treatment and management such as in situ cancer, breast
reconstruction, then the role of surgery is clear – at least
for the present time. Perhaps improvements in health
education, elimination/reduction of risk factors predis-
posing to breast cancer, developments in our understand-
ing of nutrient-gene interactions central to carcinogenesis,
and the possibility of chemoprevention, may obviate the
need for surgery. Whilst we may be witnessing the end of
the beginning for the breast surgical oncologist, at the
present time surgery still has a prime position in the man-
agement of patients with breast cancer.
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